The invention discloses an
umbilical cord blood
Treg cell in-vitro amplification method based on trophoblastic cells and application. The specific technical method comprises the steps that firstly,
umbilical cord Wharton's jelly mesenchymal stem cells are adopted as the trophoblastic cells to induce preliminary proliferation of Treg cells in
umbilical cord blood mononuclear cells; then, pure Tregcells are obtained through
magnetic bead sorting; and finally, the Treg cells are stimulated to be rapidly amplified by using optimized amplification factors. According to the amplification method, human AB
plasma, IL-2, rapamycin, an RARA
agonist and
a DNA methyltransferase inhibitor are used as the optimized amplification factors, and a large number of umbilical
cord blood Treg cells with high purity and
high activity can be prepared within two weeks.
Umbilical cord blood is used as a
raw material for
Treg cell amplification, batch preparation can be achieved, and
Treg cell quality fluctuation caused by individual differences of samples can be reduced. The umbilical
cord blood Treg cells have low
immunogenicity and can be used as universal cells for
clinical research, such as autoimmunediseases, graft-versus-host diseases and the like.